康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02162 康诺亚-B

休市中 07-03 16:08:15

81.350

+6.400

+8.54%

最高81.600	最低74.950	成交量450.36万
今开76.300	昨收74.950	日振幅8.87%
总市值243.24亿	流通市值243.24亿	总股本2.99亿
成交额3.57亿	换手率1.51%	流通股本2.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"康诺亚-B","latestPrice":81.35,"timestamp":1783066095003,"preClose":74.95,"halted":0,"volume":4503635,"delay":0,"changeRate":0.08539026017344885,"floatShares":299000000,"shares":299000000,"eps":-2.208243184938223,"marketStatus":"休市中","change":6.4,"latestTime":"07-03 16:08:15","open":76.3,"high":81.6,"low":74.95,"amount":356751263,"amplitude":0.088726,"askPrice":81.35,"askSize":3500,"bidPrice":81.15,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-2.2394591880760935,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783301400000},"marketStatusCode":7,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":74.95,"openAndCloseTimeList":[[1783042200000,1783051200000],[1783054800000,1783065600000]],"volumeRatio":0.9323340568848286,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162","defaultTab":"news","newsList":[{"id":"1149729025","title":"康诺亚-B 6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1149729025","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149729025?lang=zh_cn&edition=full","pubTime":"2026-07-03 18:14","pubTimestamp":1783073671,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司（股票代码：02162）于2026年7月3日发布2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司已发行普通股总数（不含库存股）维持在298,735,566股，未发生任何新增发行、购回或注销活动。\n公司法定/注册股本保持在500,000,000股，面值每股0.0001美元，注册股本总额为50,000美元。报告期内并无库存股变动，也未出现可转换债券、股份期权或股权激励计划的变动。\n公告同时确认，公司截至本月底已符合香港联交所关于公众持股量的相关规定。本次公告由执行董事Bo CHEN博士签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176827940","title":"异动解读｜康诺亚-B盘中上涨9.4%，医保商保双目录政策催化叠加长效AD赛道估值重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=1176827940","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176827940?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:17","pubTimestamp":1782958621,"startTime":"0","endTime":"0","summary":"7月2日，康诺亚-B盘中上涨9.4%，报77.4港元，成交额2.03亿港元，所在生物科技板块整体走强。消息面上，多重利好持续共振：国家医保局此前公示557个药品通过基本医保目录初审、54个药品通过商保创新药目录初审，\"医保+商保\"双目录谈判进入实质性阶段，市场对高临床价值创新药放量预期升温。康诺亚旗下CM512同属长效AD赛道，半衰期约70天，有望支持3至6个月给药间隔。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159164688","title":"港股生物医药板块反弹，荣昌生物涨超16%，创新药主线全面爆发","url":"https://stock-news.laohu8.com/highlight/detail?id=1159164688","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159164688?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:55","pubTimestamp":1782701710,"startTime":"0","endTime":"0","summary":"6月29日，港股生物医药股集体走强，荣昌生物涨超16%，康诺亚-B、诺诚健华、康方生物均涨超12%。板块上涨主要受创新药出海、BD交易活跃及临床管线进展预期带动，资金加速回流创新药和CXO方向。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09926","09969","03347","09995","02269","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647475483","title":"创新药概念全线扬升 晶泰控股(02228)涨逾14% 机构指创新药仍为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2647475483","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647475483?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:33","pubTimestamp":1782700428,"startTime":"0","endTime":"0","summary":"消息面上，华鑫证券新近研究表示，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。以恒瑞医药为代表的创新药企业，创新药的收入比重持续提升。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984679","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000165453.HKD","IE00BZ08YR35.GBP","LU2476274308.USD","LU0880133367.SGD","LU1720050803.USD","LU0072913022.USD","02162","LU1960683339.HKD","LU0140636845.USD","06978","LU0326950275.SGD","LU0348735423.USD","LU0348825331.USD","02228","LU0348783233.USD","LU1951186391.HKD","LU0417516571.SGD","06855","01530","LU0315179316.USD","LU1961090484.USD","LU0067412154.USD","LU2476274720.SGD","LU1226287792.SGD","09969","IE00B543WZ88.USD","LU1226288253.USD","02637","LU1328277881.USD","09995","IE00B5MMRT66.SGD","02157","LU0348767384.USD","01093","BK1574","LU1226287529.USD","159992","IE00BZ08YS42.EUR","LU0540923850.HKD","BK1141","LU0634319403.HKD","LU0348784397.USD","BK1583","LU1969619763.USD","09926","LU1008478684.HKD","LU0417516902.SGD","LU0348766576.USD","LU0348827113.USD","LU1993786604.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101768480","title":"异动解读｜康诺亚-B盘中上涨5.46%，艾伯维百亿美元收购Apogee持续催化长效AD赛道估值重塑","url":"https://stock-news.laohu8.com/highlight/detail?id=1101768480","media":"行情直击","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101768480?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:02","pubTimestamp":1782698550,"startTime":"0","endTime":"0","summary":"6月29日，康诺亚-B盘中上涨5.46%，报70.15港元，成交额1.17亿港元。消息面上，艾伯维此前宣布拟以约109亿美元收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易持续验证跨国药企对长效特应性皮炎资产战略价值的高度认可。康诺亚旗下CM512同属长效AD赛道，半衰期约70天，有望支持3至6个月给药间隔。此外，公司此前已收到吉利德收购Ouro Medicines的2.57亿美元首付款及阿斯利康4500万美元里程碑付款，现金流显著增厚，全球价值兑现路径进一步明晰。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167943014","title":"异动解读｜康诺亚-B盘中上涨5.65%，艾伯维百亿美元收购Apogee持续催化长效AD赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=1167943014","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167943014?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:08","pubTimestamp":1782439732,"startTime":"0","endTime":"0","summary":"6月26日，康诺亚-B盘中上涨5.65%，报65.6港元，成交额7981.71万港元。消息面上，艾伯维近日宣布拟以约109亿美元收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易反映跨国药企对长效特应性皮炎资产的战略价值及峰值销售潜力给予高度认可。康诺亚旗下CM512同属长效AD赛道，若临床数据支持延长给药间隔，其市场竞争力有望显著提升。国金证券维持公司\"买入\"评级，指出长效AD产品价值获MNC进一步验证。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126071164","title":"港股直击 | 部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126071164","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126071164?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:06","pubTimestamp":1782439605,"startTime":"0","endTime":"0","summary":"部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%，康龙化成升3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184186957","title":"港股直击 | 部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1184186957","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184186957?lang=zh_cn&edition=full","pubTime":"2026-06-26 10:03","pubTimestamp":1782439382,"startTime":"0","endTime":"0","summary":"部分医药股、医药外包股造好，中国抗体、康诺亚升5%，泰格医药升4%，康龙化成升3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","02162","03347"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645600470","title":"国金证券：长效AD产品价值进一步获得MNC验证 维持康诺亚-B(02162)“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2645600470","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645600470?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:42","pubTimestamp":1782182527,"startTime":"0","endTime":"0","summary":"长效AD产品价值或将进一步获MNC验证AD患者治疗周期长、复发率高，疗效和给药便利性对患者而言至关重要，因此在疗效接近或具备非劣基础上，若能实现更低频给药，产品有望在维持治疗和商业化竞争中形成明显优势。Apogee的IL-13长效抗体获得MNC艾伯维青睐，说明MNC对长效AD资产的战略价值和峰值销售潜力给予厚望，长效AD产品价值进一步获得MNC验证。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196805443","title":"异动解读｜康诺亚-B盘中上涨5.38%，艾伯维百亿美元收购Apogee验证长效AD产品价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1196805443","media":"行情直击","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196805443?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:24","pubTimestamp":1782181472,"startTime":"0","endTime":"0","summary":"6月23日，康诺亚-B盘中上涨5.38%，报59.95港元，成交额5695.4万港元。消息面上，艾伯维宣布拟以约109亿美元收购Apogee公司，其核心产品为长效IL-13单抗APG777，交易预计于三季度完成。该收购反映跨国药企对长效特应性皮炎资产的战略价值及峰值销售潜力给予高度认可。康诺亚旗下CM512同属长效AD赛道，若临床数据支持延长给药间隔，其市场竞争力有望显著提升。此外，公司核心产品康悦达已获批多项适应症并纳入医保，商业化放量持续推进。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001206","title":"医药板块逆市走高 山东新华制药(00719)涨23.59%、康诺亚-B(02162)涨5.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001206","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645001206?lang=zh_cn&edition=full","pubTime":"2026-06-23 10:08","pubTimestamp":1782180500,"startTime":"0","endTime":"0","summary":"市场交易结构出现变化，医药与科技板块不再呈现明显跷跷板效应，医疗服务、CXO赛道带动板块韧性修复。临近二季度末，市场开始提前交易行业业绩预期，资金重点布局两大主线，分别为商业化放量提速的创新药标的，以及受益于投融资回暖的CXO、生命科学上游龙头。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/NmI5OTlmYjAxY2FmOGFlNWZkYjg2NDM0MTE4MzUwMDcw.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984274","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","LU0516422366.SGD","LU0516423091.SGD","LU0052750758.USD","IE00BPRC5H50.USD","02268","LU0348783233.USD","LU0359202008.SGD","LU1242518857.USD","06990","LU2328871848.SGD","LU1880383366.USD","BK1576","09688","BK1191","02269","IE00B5MMRT66.SGD","LU0039217434.USD","BK1161","LU0856984785.SGD","LU0456827905.SGD","IE00B0JY6N72.USD","LU0307460666.USD","LU0326950275.SGD","LU0588546209.SGD","00719","LU1720050803.USD","LU0979878070.USD","LU2039709279.SGD","LU3063872942.SGD","LU0140636845.USD","LU0327786744.USD","09926","BK1589","159938","LU0320764599.SGD","09939","09995","LU1303224171.USD","01877","LU0359201612.USD","LU0417516902.SGD","02162","09969","LU0051755006.USD","SG9999002562.SGD","LU0516422952.EUR","BK1583","LU1251922891.USD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131093292","title":"港股直击 | 生物医药股及医药外包股造好，康宁杰瑞制药、康诺亚升7%，荣昌生物、昭衍新药升5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131093292","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131093292?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:49","pubTimestamp":1782179371,"startTime":"0","endTime":"0","summary":"生物医药股及医药外包股造好，康宁杰瑞制药、康诺亚升7%，荣昌生物、昭衍新药升5%，药明巨诺升3%。","market":"us","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","09966","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001593","title":"港股异动 | 康诺亚-B(02162)早盘涨超6% 艾伯维斥资超百亿美元收购Apogee 长效AD产品获MNC验证","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001593","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645001593?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:44","pubTimestamp":1782179097,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，康诺亚-B早盘涨超6%，截至发稿，涨6.44%，报60.35港元，成交额2624.42万港元。消息面上，艾伯维宣布拟以约109亿美金收购Apogee公司，其核心产品为长效IL-13单抗APG777，该交易预计于2026年三季度完成。国金证券指出，此次收购说明MNC对长效AD资产的战略价值和峰值销售潜力给予厚望，长效AD产品价值进一步获得MNC验证。若临床数据可支持延长给药间隔，其长效优势有望显著提升其市场竞争力。除了CM512外，公司年内仍有多项催化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4132","BK4585","02162","BK1161","BK4588","AD","BK1587","VXUS","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644314776","title":"创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644314776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644314776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:21","pubTimestamp":1781749308,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念普涨，截至发稿，再鼎医药 涨6.34%，康方生物涨5.96%，药明康德涨3.59%，康诺亚-B涨3.49%，亚盛医药涨3.45%，药明生物涨3.08%，金斯瑞生物科技涨2.93%，百济神州涨2.60%。华鑫证券研究称，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"sh","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984066","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000306701.USD","LU0561508036.HKD","LU1961090484.USD","SG9999002463.SGD","LU0348784397.USD","BK4531","LU0417516571.SGD","LU0140636845.USD","LU1794554557.SGD","02359","LU2328871848.SGD","LU0516422952.EUR","BK1587","LU2488822045.USD","LU0456846285.SGD","LU2045819591.USD","BK1588","IE00BPRC5H50.USD","LU0516423174.USD","LU2476274308.USD","BK1521","BK1583","159992","BK1161","BK4526","ZLAB","06978","09926","LU0516423091.SGD","LU1720050803.USD","LU2242644610.SGD","HK0000320223.HKD","02162","LU1969619763.USD","06855","LU0307460666.USD","LU1719994722.HKD","LU1303224171.USD","BK1141","01548","LU0979878070.USD","BK1589","06160","LU0588546209.SGD","09688","HK0000306685.HKD","LU0326950275.SGD","02269","LU0348827113.USD","LU0516422366.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643822932","title":"【券商聚焦】交银国际：医药行业上半年表现整体稳健 下半年内部分化或加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2643822932","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643822932?lang=zh_cn&edition=full","pubTime":"2026-06-15 10:21","pubTimestamp":1781490116,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，医药行业在1H26表现整体稳健、但内部分化也较为明显。短期关注出海交易、业绩表现和利好政策落地。推荐高景气度赛道中、投资性价比较高的头部玩家，包括药明合联、凯莱英和康龙化成。2026年港股龙头收入和净利润增速有望稳定在双位数。板块复苏积极信号已经出现。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjBmYTFlMmI3YzYzNjVkMWZlODgyMTcwNTE1Njk3NDY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983754","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0502904849.HKD","01093","09966","01276","LU2097828631.EUR","HK0000306685.HKD","LU2399975544.HKD","SG9999002562.SGD","01530","LU0456827905.SGD","LU1226287875.USD","01177","LU1960683339.HKD","HK0000320264.USD","LU0737861772.HKD","LU0819121731.USD","02269","06996","01801","09996","LU1242518857.USD","LU0051755006.USD","06821","IE00BZ08YR35.GBP","LU3063872942.SGD","02273","LU0140636845.USD","03759","01951","03692","06078","BK1191","LU1688375341.USD","03329","09926","IE00B0JY6N72.USD","LU0320764599.SGD","06160","BK1576","02162","00013","02268","02096","02596","06990","LU0181495838.USD","LU0348827113.USD","01548","01952","LU1880383366.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642254781","title":"医药板块集体回升 科伦博泰生物(06990)涨7.20%、荣昌生物(09995)涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642254781","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642254781?lang=zh_cn&edition=full","pubTime":"2026-06-12 13:30","pubTimestamp":1781242214,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股医药板块集体回升，科伦博泰生物 涨7.20%，荣昌生物涨6.53%，康诺亚-B涨5.58%，复宏汉霖涨5.36%，康方生物涨5.07%，君实生物涨4.61%，药明合联涨4.06%，诺诚健华涨3.96%。英伟达同时为 Abridge 投资方，新模型基于英伟达开放模型套件 Nemotron 训练，Abridge 将采用去标识化临床数据进行定制优化，预计 2026 年晚些时候上线。东莞证券研报认为，受行业合规整顿以及消费疲软等因素影响，2025年医药生物行业整体归母净利润同比有所下滑。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OWU0MGRiNDM1NDA5NTM4MzU5OQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1983673","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","LU2476274308.USD","09939","LU0348825331.USD","09995","BK1587","LU2399975544.HKD","LU0417516902.SGD","LU0348783233.USD","06990","LU0417516738.SGD","LU1720050803.USD","LU0417516571.SGD","LU0561508036.HKD","BK1141","02696","LU0348784397.USD","LU0348827113.USD","HK0000320223.HKD","BK1574","HK0000320264.USD","BK0239","IE00BPRC5H50.USD","BK1161","LU0348766576.USD","01877","LU2328871848.SGD","688331","LU2476274720.SGD","09926","LU0634319403.HKD","159938","LU0540923850.HKD","SG9999014674.SGD","LU1794554557.SGD","02268","LU0348767384.USD","LU1969619763.USD","LU1064130708.USD","02162","LU2148510915.USD","LU0348735423.USD","LU1064131003.USD","LU1961090484.USD","LU2488822045.USD","BK1583","HK0000306701.USD","09969","HK0000165453.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642825996","title":"港股异动 | 康诺亚-B(02162)涨近6% Ouro Medicines并购协议已完成 公司已收到2.57亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2642825996","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642825996?lang=zh_cn&edition=full","pubTime":"2026-06-12 11:22","pubTimestamp":1781234541,"startTime":"0","endTime":"0","summary":"消息面上，近日，康诺亚-B发布公告，有关出售集团于Ouro Medicines的少数股权，2026年6月5日，集团NewCo合作企业Ouro Medicines通过该等公告披露的并购协议现已正式完成，集团已收到2.57亿美元首付款。作为Ouro Medicines的股东，集团获得约2.57亿美元首付款及有权获得最高约7000万美元里程碑付款。此外，集团与Ouro Medicines于2024年11月订立的独家许可协议继续有效，最高6.1亿美元的里程碑付款及销售净额的分层特许权使用费由吉利德与Lakefront履行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1161","02162","BK1574","BK1583","BK4585","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641194281","title":"康诺亚-B(02162)：已就出售Ouro Medicines股权事项收到2.57亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2641194281","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641194281?lang=zh_cn&edition=full","pubTime":"2026-06-05 12:26","pubTimestamp":1780633592,"startTime":"0","endTime":"0","summary":"根据并购协议条款，吉利德以16.75亿美元首付款及最高5亿美元的潜在里程碑付款，收购了Ouro Medicines全部股权。作为Ouro Medicines的股东，集团获得约2.57亿美元首付款及有权获得最高约7000万美元里程碑付款。此外，集团与Ouro Medicines于2024年11月订立的独家许可协议继续有效，最高6.1亿美元的里程碑付款及销售净额的分层特许权使用费由吉利德与Lakefront履行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450598.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康诺亚-B(02162)：已就出售Ouro Medicines股权事项收到2.57亿美元首付款","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02162","BK1161","BK1583","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152093512","title":"港股创新药概念股普涨，康诺亚-B、科伦博泰生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1152093512","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152093512?lang=zh_cn&edition=full","pubTime":"2026-06-05 09:54","pubTimestamp":1780624485,"startTime":"0","endTime":"0","summary":"6月5日，港股创新药概念股普涨，$康诺亚-B(02162)$、$科伦博泰生物(06990)$涨超5%，$恒瑞医药(01276)$、$信达生物(01801)$涨超4%，$药明康德(02359)$、$歌礼制药-B(01672)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fd680cd945fd32917c8ece66ec685e5f"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","02162","VXUS","LU0196878994.USD","BK1161","BK1587","BK4588","06978","06990","BK1574","BK4585","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173323760","title":"康诺亚-B 2026年5月月报：无新增发行或股份变动，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1173323760","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173323760?lang=zh_cn&edition=full","pubTime":"2026-06-02 16:47","pubTimestamp":1780390033,"startTime":"0","endTime":"0","summary":"康诺亚生物医药科技有限公司于2026年6月2日披露了截至2026年5月31日止的证券变动月报表。本次公告显示，公司法定股本及已发行股份数量与上月保持一致，股本总体维持稳定。公司同时披露，截至2026年5月31日，已充分满足香港联合交易所有限公司《上市规则》关于公众持股量的要求。本次公告由执行董事Bo CHEN博士签署。公司表示将继续遵守香港联交所《上市规则》及相关法律法规的要求，合法合规地履行信息披露义务。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2701},{"period":"1month","weight":0.3684},{"period":"3month","weight":0.1402},{"period":"6month","weight":0.522},{"period":"1year","weight":0.7495},{"period":"ytd","weight":0.522}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0891},{"period":"3month","weight":-0.0703},{"period":"6month","weight":-0.1135},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"康诺亚生物医药科技有限公司是一家生物科技公司，专注于自主发现及开发自体免疫及肿瘤治疗领域的创新生物疗法的公司。该公司还专注于医药产品的研究和开发。该公司的主要产品有CM310、CM326、CM313和CM383，可治疗各种成人、青少年及儿童I型免疫性疾病，例如中重度特应性皮炎、中重度哮喘、慢性鼻賨炎伴鼻息肉、过敏性鼻炎，亦可能可以治疗慢性阻塞性肺疾病。该公司还建立了涵盖生物药开发的关键功能的全面一体化平台。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.062159},{"month":2,"riseRate":0.6,"avgChangeRate":0.057033},{"month":3,"riseRate":0.4,"avgChangeRate":0.01927},{"month":4,"riseRate":1,"avgChangeRate":0.079263},{"month":5,"riseRate":0.2,"avgChangeRate":-0.114444},{"month":6,"riseRate":1,"avgChangeRate":0.128513},{"month":7,"riseRate":0.6,"avgChangeRate":0.135688},{"month":8,"riseRate":0.6,"avgChangeRate":0.038036},{"month":9,"riseRate":0.8,"avgChangeRate":0.042936},{"month":10,"riseRate":0.4,"avgChangeRate":0.003137},{"month":11,"riseRate":0.6,"avgChangeRate":0.04569},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144855}],"exchange":"SEHK","name":"康诺亚-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康诺亚-B,02162,康诺亚-B股票,康诺亚-B股票老虎,康诺亚-B股票老虎国际,康诺亚-B行情,康诺亚-B股票行情,康诺亚-B股价,康诺亚-B股市,康诺亚-B股票价格,康诺亚-B股票交易,康诺亚-B股票购买,康诺亚-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康诺亚-B(02162)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康诺亚-B(02162)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}